Regulation of pharmaceutical markets in Germany: Improving efficiency and controlling expenditures?

International Journal of Health Planning and Management

Volumn 20, Issue 4, 2005, Pages 329-349

  Busse, Reinhard ^a   Schreyögg, Jonas ^a   Henke, Klaus Dirk ^a  

^a TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Drugs; Efficiency; Germany; Pharmaceuticals; Regulation

Indexed keywords

NON PRESCRIPTION DRUG;

MARKET; PHARMACEUTICAL INDUSTRY; REGULATORY APPROACH;

ARTICLE; COST CONTROL; DRUG INDUSTRY; DRUG MARKETING; FINANCIAL MANAGEMENT; GERMANY; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; LAW; MEDICAL DECISION MAKING; PHARMACY; PHYSICIAN ATTITUDE; PRESCRIPTION;

COST CONTROL; DRUG INDUSTRY; EFFICIENCY, ORGANIZATIONAL; GERMANY; GOVERNMENT REGULATION; HEALTH EXPENDITURES;

CENTRAL EUROPE; EURASIA; EUROPE; GERMANY;

EID: 28944448328     PISSN: 07496753     EISSN: None     Source Type: Journal    
DOI: 10.1002/hpm.818     Document Type: Article

References (28)

1. Advisory Council for the Concerted Action in Health Care. 2001. Appropriateness and Efficiency, Vol. I-III. Bonn.
2. Ärztezeitung. 2003. http://www.aerztezeitung.de/docs/2003/03/11/046a0408.asp?cat=/politik/ arzneimittelversorgung/aut_idem, accessed 5/6/2003.
3. BAH (Federal Association of Pharmaceutical Manufacturers). 2002. Der Arzneimittelmarkt in Deutschland in Zahlen 2001. Bonn.
4. BfArM (Federal Institute for Drugs and Medical Devices). 2003. Homepage: http://www.bfarm.de/de/gb_ver/index.html, accessed 8/20/2003.
5. BKK (Association of Company-Based Sickness Funds). 2004. Official announcement on 1/11/2004.
6. BMGS (Federal Ministry of Health and Social Security). 2002. Social security at a glance. Bonn.
7. Breyer F. 2002. Reimbursement and cost containment - a German perspective. Pharmacoeconomics 20(Suppl. 3): 87-94.
8. Busse R. 2000. Health Care Systems in Transition - Germany. European Observatory on Health Care Systems: Copenhagen.
9. Busse R, Howorth C. 1996. Germany's spending cap for pharmaceuticals - Effects on cost and quality. In Fixing Health Budgets - Experiences from Europe and North America, Schwartz FW, Glennerster H, Saltman RB (eds). Wiley: Chichester; 109-127.
10. Busse R, Wörz M. 2003. German plans for 'health care modernization'. Eurohealth 9(1): 21-24.
11. Federal Statistical Office (Statistisches Bundesamt). 2003a. Price index, http://www.destatis.de/indicators/d/vpi001vj.htm, accessed 5/3/2003.
12. Federal Statistical Office. 2003b. Gesundheit, Ausgaben und Personal 2001. Wiesbaden.
13. Giuliani G, Selke G, Garattini L. 1998. The German experience in reference pricing. Health Policy 44: 73-85.
14. Hellerstein JK. 1998. The importance of the physician in the generic versus trade-name prescription decision. Rand J Econ 29: 108-136.
15. Henke K-D. 2001. The Allocation of National Ressources in Health Care in Germany Between Competition and Solidarity. In Gesundheitssysteme am Scheideweg: Zwischen Wettbewerb und Solidarität, Henke K-D, Dräger C (eds). Nomos: Baden-Baden; 47-57.
16. Henke K-D, Ade C, Murray MA. 1994. The German health care system: structure and changes. J Clin Anesth 6: 252-262.
17. Henke K-D, Murray MA, Ade C. 1994. Global budgeting in Germany: lessons for the United States. Health Aff 13(3): 7-21.
18. Pharmafakt (Company for market research). 2002. Random test on substituted prescriptions in southern Germany based on data from a data processing centre for pharmacy bills of the Association of Sickness Funds physicians in southern Germany, conducted in October 2002 on behalf of the pharmaceutical industry. München. Unpublished.
19. Research Institute of Regional Sickness Funds (WIdO). 2004. GKV-Arzneimittelindex: Preisinfo 02/2003. Bonn.
20. Schneeweiss S, Schöffski O, Selke GW. 1998. What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution? Health Policy 44: 253-260.
21. Schreyögg J, Bussse R. 2005. Drug budgets and effects on physicians' prescription behaviour: new evidence from Germany. Journal of Pharmaceutical Finance, Economics & Policy 14: 77-95.
22. Stargardt T, Schreyögg J, Busse R. 2005. Arzneimittelfestbeträge: Gruppenbildung, Preisberechnung mittels Regressionsverfahren und Wirkungen. Gesundheitswesen 67: 469-478.
23. Schöffski O. 1996. Consequences of implementing a drug budget for office-based physicians in Germany. Pharmacoeconomics 10(Suppl. 2): 37-47.
24. Schulenburg JM. 1997. Management of cost containment and utilization of pharmaceuticals in Germany. Health Policy 41(Suppl.): 45-53.
25. Schwabe U, Paffrath, D. 2003. ArzneiverordnungsReport 2002. Springer: Berlin.
26. VFA (Association of research based pharmaceutical companies). 2003. Press release no. 004/2003. Berlin.
27. VFA (Association of research based pharmaceutical companies). 2002. Statistics 2002. Berlin.
28. VFA (Association of research based pharmaceutical companies). 2003. Statistics 2003. Berlin.